-
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
NASDAQ: $REGN TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and… Source: Read More
-
New Hope for Advanced Low-Grade Serous Ovarian Cancer: The Potential of Ubamatamab
NASDAQ: $REGN A Breakthrough in Ovarian Cancer Research Recent clinical findings have brought a glimmer of optimism for patients battling advanced low-grade serous ovarian cancer. A novel therapeutic agent known as ubamatamab (MUC16xCD3) has shown promising results in initial clinical trials, highlighting a potential new path forward for those who have exhausted standard treatment options.…
-
A Breakthrough in Rare Disease Care: FDA Approves Pasatru (garetosmab) for FOP
NASDAQ: $REGN A New Chapter for FOP Patients For individuals living with Fibrodysplasia Ossificans Progressiva (FOP), a rare and debilitating genetic disorder, the medical landscape has just shifted significantly. The FDA has officially approved Pasatru (garetosmab), a new therapeutic option designed to help manage this challenging condition. Understanding FOP FOP is a rare genetic condition…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-01-2026 TO 02-07-2026
The Groundhog sees his shadow, so hunker down and trade more to warm up! 😉 We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions…
$AMGN, $AZN, $BMY, $BSX, $DNLI, $GKOS, $GSK, $INCY, $JAZZ, $LLY, $MRNA, $PHVS, $REGN, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases